# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001144204-18-018393
Filing Date
2018-04-02
Accepted
2018-04-02 07:14:05
Documents
3
Effectiveness Date
2018-04-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tv490063_defa14a.htm | DEFA14A | 16055
2 | GRAPHIC | image_001.jpg | GRAPHIC | 524387
3 | GRAPHIC | image_002.jpg | GRAPHIC | 923626
| Complete submission text file | 0001144204-18-018393.txt |  | 2011814

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33357 | Film No.: 18727221
SIC: 2836 Biological Products, (No Diagnostic Substances)